Showing 5381-5390 of 7146 results for "".
- Foamix Update: Nine Trials in Five Postershttps://practicaldermatology.com/news/foamix-update-nine-trials-in-five-posters/2460192/Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-t
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderat
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of
- UCB’s Bimekizumab Performs Well in Phase 3 Psoriasis Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-phase-3-psoriasis-study/2460186/UCB’s bimekizumab, an IL-17A and IL-17F inhibitor, bested placebo and Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic plaque psoriasis and improving their symptoms, the company reports. BE VIVID is the first of three Phase 3
- Psoriasis Linked to Developing and Dying from Cancerhttps://practicaldermatology.com/news/psoriasis-linked-to-developing-and-dying-from-cancer/2460185/Psoriasis may increase the risk for certain cancers, according to a review of 58 studies published in JAMA Dermatology. Moreover, the risk of dying from certain site-specific cancers was elevated in those with severe psoriasis. Specifically, severe psoriasi
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- Obagi Program at ASDS to Focus on Inclusionhttps://practicaldermatology.com/news/obagi-program-at-asds-to-focus-on-inclusion/2460183/Obagi and actor, producer and activist, Priyanka Chopra Jonas, will lead a panel of top dermatologists in a discussion about the importance of diversity and inclusion in medical aesthetics during the annual meeting of the American Society for Dermatologic Surgery (ASDS) in Chicago next week. 
- Allergan Shareholders Approve Proposed Acquisition by AbbViehttps://practicaldermatology.com/news/allergan-shareholders-approve-proposed-acquisition-by-abbvie/2460181/Allergan’s shareholders approved the previously announced proposed acquisition of Allergan by AbbVie Inc. More than 99 percent of the votes cast at both a special court-ordered meeting of shareholders and at an extraordinary general meeting of shareholders were in favor of the tra
- Positive Top-line Results Seen in Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue Deep Partial-thickness Thermal Burnshttps://practicaldermatology.com/news/positive-top-line-results-seen-in-pivotal-phase-3-clinical-trial-of-stratagraft-regenerative-tissue-deep-partial-thickness-thermal-burns/2460178/Mallinckrodt plc's pivotal Phase 3 clinical trial evaluating the efficacy and safety of a single application of StrataGraft regenerative tissue in the treatment of deep partial-thickness thermal burns met both primary endpoints. The pivotal open-label, controlled, randomized, multic
- EADV News: Psoriasis Largely Undertreated, Travels with Anxietyhttps://practicaldermatology.com/news/eadv-news-psoriasis-largely-undertreated-travels-with-anxiety/2460175/Many psoriasis patients remain un- or undertreated, with an average diagnosis time of five years, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. In the study of 650 psoriasis patients in Germany, more than half of patients (56 percen